Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg produces significant, sustained weight loss (mean 11.80% body weight reduction) and improves cardiometabolic markers in non-diabetic overweight or obese adults compared to placebo.
For non-diabetic adults with obesity, once-weekly 2.4 mg subcutaneous semaglutide is a highly effective intervention for significant weight loss (approx. 12% body weight) and metabolic improvement. While gastrointestinal side effects are common, they are generally manageable and transient.
The findings indicated that, in comparison to the placebo group, semaglutide caused a significant and sustainable reduction in the percentage of body weight (BW; mean difference [MD]: (cid:1)11.80% [95% confidence interval {CI} (cid:1)12.93, (cid:1)10.68]; P < 0.00001)... Moreover, it achieved a higher proportion of patients who experienced weight loss exceeding 5%, 10%, 15% and 20%. Furthermore, semaglutide showed significant efficacy in controlling blood pressure, blood sugar levels, C-reactive protein levels, and lipid profiles.
Why this rating
Based on a systematic review and meta-analysis of 6 high-quality RCTs involving 3962 participants.
Source
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial
Wenhui Qin et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15386
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →